Biased research, aggressive sales, harmful drugs
The Health Policy Exchange
MAY 20, 2013
Food and Drug Administration to market a new drug is a critical waypoint along the path to profits for pharmaceutical manufacturers. Unfortunately, recent case studies have illustrated that FDA approval does not necessarily provide assurances of effectiveness and safety. The size of average doses would more than triple.
130 
Let's personalize your content